These agents include IL-6R monoclonal antibodies which have been shown to improve chemotherapy response in a subcutaneous transplant model of iCCA,31 as well as several FGFR inhibitors already approved for second-line use in iCCA.32 This evidence concerns the gene IL6R and infantile convulsions and choreoathetosis.